Your Health, We Care
On March 19, 2024, Takeda Pharmaceutical Company Limited announced that the U.S. Food and Drug Administration (FDA) had approved the supplemental New Drug Application (sNDA) for ponatinib (Iclusig, generic name: ponatinib) for the treatment of newly diagnosed adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
On December 18, 2020, the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for Takeda Pharmaceutical’s ponatinib (Iclusig, generic name: ponatinib) for the treatment of adult patients with chronic-phase chronic myeloid leukemia (CML) who are resistant or intolerant to prior therapies.
On December 14, 2012, the U.S. Food and Drug Administration (FDA) approved ponatinib (Iclusig) for the treatment of two rare types of leukemia.
Ponatinib is an oral targeted drug specifically indicated for the treatment of c···【more】
Release date：2026-01-20Recommended：130
Takeda Pharmaceutical Company Limited (Takeda) recently announced that the U.S. ···【more】
Release date：2026-01-20Recommended：162
Ponatinib, a third-generation BCR-ABL tyrosine kinase inhibitor (TKI), was devel···【more】
Release date：2026-01-20Recommended：152
On March 19, Takeda announced that the U.S. Food and Drug Administration (FDA) h···【more】
Release date：2026-01-20Recommended：180
Takeda Pharmaceutical Company Limited (Takeda) recently announced that the Phase···【more】
Release date：2026-01-20Recommended：189
Telegram name: Vira
Name: LUCIUS
No.:0085253923643
